Safety Takeaway Approved Use: When used under medical supervision for EPP treatment, the benefits of MT-1 outweigh the risks
It takes just minutes to make but the benefits last so much longer
O., Giri, N., McReynolds, L
doi: 10.3390/antiox10071025 212 ChenYMTuCJHungKYWuKDTsaiTJHsiehBS
In the larger SELECT trial in 2023, patients with heart failure, atherosclerotic disease, and overweight or obesity, treated with semaglutide 2.4 mg showed reduction in major adverse cardiac events (MACE) and heart failure end points regardless of heart failure subgroup being HFrEF or HFpEF [56,57,58]